Vaccine inequity will cost the world trillions of dollars, WHO Foundation warns

Vaccine inequity will cost the world trillions of dollars, WHO Foundation warns


The CEO of the WHO Foundation has told CNBC that the global economy will lose “trillions of dollars” if more Covid-19 vaccines aren’t delivered worldwide.

Anil Soni, who became the Foundation’s first CEO in January 2021, said “the governments of Europe and the West have a clear obligation to donate excess doses and to put money on the table to buy the vaccines, the volumes necessary to deliver to 70% of the world’s population this year.”

The World Health Organization has set a target for 70% of the global population to be vaccinated by mid-2022.

Speaking in late February for this week’s episode of CNBC’s “Equity and Opportunity” on vaccine equity, Soni said it is a “moral imperative” to vaccinate the world against Covid.

“We live in a world in which we see the effects of deep, structural generations-long inequity. This is an opportunity to do something very different and show that history can be corrected. That we can achieve the moral victory of an equitable response where everyone in the world, all of us have equal value, receives the same access to this life-saving technology,” Soni said.

“But epidemiologically and economically, vaccine inequity is self-defeating, the numbers just make that clear. We’re going to lose trillions of dollars in the global economy if we don’t achieve high vaccine coverage, because what you’ll have in global supply chains is materials not able to come from the countries in which you have continued lockdowns, continued high rates of transmission of Covid-19.”

Soni said that even with vaccines, the spread of the most recent variant, omicron, had been “breathtaking,” and if large populations of the world remain unvaccinated, future variants could develop which may be resistant to vaccinations.

The WHO Foundation was established in 2020 to support the World Health Organization’s work in addressing the biggest global health challenges.

Not enough progress

Soni told CNBC that he was proud of the “tremendous progress” achieved through vaccines in the first two years of the Covid crisis. But he said the pandemic won’t be over until the 70% global target is met, and there hasn’t been enough progress on that front.

Last week, the U.N. reported that while more than 10.5 billion vaccine doses had been administered globally, only about 13% of those in low-income countries had been vaccinated, compared with nearly 70% in high-income ones.

“We have the ability to do it, we can make it happen, but we’ve got to act very differently in the next few months to achieve that target. We have to mobilize more resources, money to buy the vaccines, we have to share doses, and critically, we have to ensure effective delivery in countries around the world to go from the billion doses that have been delivered in low-income countries to hitting that 70% target,” Soni said.

Fundraising campaign

In 2021, the WHO Foundation launched the “Go Give One” fundraising campaign.

The campaign encourages everyone to contribute $5, with 95% of the money going toward buying a single vaccine through the international initiative COVAX — co-led by the WHO, the Coalition for Epidemic Preparedness Innovations and vaccine alliance Gavi, alongside delivery partner UNICEF.

Soni said the campaign had raised $15 million so far, buying 3 million vaccines.

He also said the sharing of manufacturing knowledge to produce vaccines is “critically important” in achieving vaccine equity.

A shipment of AstraZeneca Covid-19 vaccine from a plane at Felix Houphouet Boigny airport in Abidjan, Ivory Coast, on Feb. 26, 2021.

Sia Kambou | Afp | Getty Images

“Manufacturers in low- and middle-income countries, in the Americas, in Asia, in Africa, have the ability to make these products and they are ready to make them,” he said.

“A number of organizations, including the World Health Organization, is facilitating the technology and the information transfer, but we need those companies in the West, in Europe, in the United States to cooperate and to see this as a win, to see this as an opportunity for them to invest in the type of capacity in these countries, in the manufacturing industry, that they simply can’t meet themselves.”

Freedom through vaccinations



Source

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Health

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]

Read More
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
Health

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a landmark decision that health experts […]

Read More
UnitedHealth Group commits to improvements after independent audit, patient backlash
Health

UnitedHealth Group commits to improvements after independent audit, patient backlash

UnitedHealthcare sign is displayed at its office building in Minnetonka, Minnesota, U.S., Dec. 11, 2025. Tim Evans | Reuters UnitedHealth Group on Friday released the first results from a sprawling independent audit of its business practices and committed to a wide range of steps to track and implement improvements in three specific areas. The health-care […]

Read More